Seed · Biotech & Pharma

Seed Biotech pitch decks mapped to value-inflecting milestones.

Seed-stage biotech investors fund a lead program toward candidate nomination or IND-enabling work. The deck must present the data package with rigor, map the development plan to milestones that step up value, and show a team that can execute translational science.

At a glance

Typical deck length
12–15 slides
Who you're pitching
Seed funds, multi-stage firms' seed practices, angels and syndicates leading or following early institutional rounds.
Lead with
Lead-program efficacy data · Development timeline · Milestone-based budget
Trusted by founders & teams at
PfizerSonyBayerMerckUPMCFarmers InsurancePella
What investors need to believe

What Seed Biotech investors need to believe.

A Biotech round at Seed turns on a handful of beliefs. Your deck should build each one before a partner has to ask.

The lead program is differentiated

Data suggests a meaningful advantage over standard of care or competing approaches.

The path to the clinic is clear

Candidate selection, IND-enabling studies and timelines are mapped realistically.

Milestones step up value

Each funded milestone is a recognizable de-risking event for the next investor.

The team can translate

Scientific founders are paired with drug-development or regulatory experience.

Metrics & proof

What to lead with at Seed.

At this stage, these are the numbers and evidence that carry the room. Each one should tie out to your model and data room.

Lead-program efficacy data

Show the key in vivo results against relevant comparators with clear statistics.

Development timeline

Map candidate nomination, IND-enabling studies and IND filing on one roadmap.

Milestone-based budget

Show cost per milestone and the runway to the next value inflection.

Competitive landscape

Compare against programs in development by mechanism and stage.

IP and exclusivity

Summarize patent coverage and expected exclusivity period.

Recommended slide order

How to structure a Seed Biotech deck.

A 12–15 slides structure tuned for this round. Tap any slide for the full guide.

  1. Title Slide

    At seed, the title slide can lean on an early proof point — a pilot customer type or a launch milestone — alongside a sharp one-liner.

  2. Problem Slide

    At seed, back the problem with early customer evidence — pilot conversations, waitlist demand or quotes from users who already rely on you.

  3. Solution Slide

    At seed, show the solution working in the real world — early users, a live product and the first evidence that it delivers the promised outcome.

  4. Why Now Slide

    At seed, pair the timing argument with early signs the window is opening — customers adopting faster than expected or new buyers appearing.

  5. Market Size Slide

    At seed, tighten the bottom-up model with real pricing signals from early customers and a sharper definition of the initial segment.

  6. Product Slide

    Present the pipeline as a value-inflection map — each program against its next milestone and data readout.

    Biotech-specific
  7. Traction Slide

    At seed, show early revenue or usage with a clear growth trend, plus retention signals that suggest product-market fit is emerging.

  8. Business Model Slide

    At seed, back the model with real pricing — early contracts, conversion from pilots or willingness-to-pay evidence from customers.

  9. Go-to-Market Slide

    At seed, show the first channel working — early conversion data, founder-led sales results or organic pull from a specific segment.

  10. Competition Slide

    Use a landscape grid by mechanism and development stage rather than a generic 2×2.

    Biotech-specific
  11. Team Slide

    Pair scientific founders with drug-development, CMC or regulatory advisors and their relevant track records.

    Biotech-specific
  12. Financials Slide

    At seed, show a basic projection driven by clear assumptions, with early revenue as the anchor and runway to Series A milestones.

  13. The Ask & Use of Funds Slide

    At seed, connect the raise to the metrics investors will expect at Series A, with use of funds weighted toward product and early go-to-market.

Objections to pre-empt

What Biotech investors will push on at Seed.

Why will this beat the competitors already in the clinic?

How the deck answers it: Show differentiation on efficacy, safety, dosing or patient selection with head-to-head or benchmark data.

Is the budget realistic for IND-enabling work?

How the deck answers it: Break out CRO and CMC costs with vendor quotes or precedent ranges.

What's the platform beyond one asset?

How the deck answers it: Show how the approach generates follow-on programs without diluting focus on the lead.

What founders say

Trusted by founders. Backed by results.

They were able to give us insight into a comprehensive and emerging landscape. They provided further resources with case studies and data to make our arguments more compelling; while being timely and communicative. They're an asset to any team moving forward.
John McTernan
Sr. Director of Strategy | Pfizer
[They] were educated in the biopharma space and was able to give us insight into the landscape. They provided further resources/data to make our arguments more compelling. He was timely and communicative. An asset to any team moving forward.
Zander Ford
Founder | Conscious Founders
(For our acquisition of Modular Water), they really built the case with deep research. Highly professional. They took the time to work through a number of iterations of the project and maintained outstanding communication. Highly recommend.
Riggs Eckleberry
CEO | OriginClear HoldCo.
FAQ

Common questions. Clear answers.

What milestones should a seed biotech round fund?
Typically the steps that make the program investable at the next stage — for many companies, candidate nomination and a meaningful portion of IND-enabling work. The right milestones depend on modality and investor.
How detailed should the science be in a seed biotech deck?
Detailed enough for a specialist to evaluate, clear enough for a generalist to follow. Keep the main deck to the decisive data and move supporting experiments to an appendix.
What does a custom engagement cost?
We're upfront about pricing: custom presentations start at $25K, and monthly packages are $15,000 — which include a team lead, researcher, analyst, and investor-relations expert for the price of one employee.
How fast can you turn it around?
Typical turnaround is 8–10 business days from the strategy session to final delivery. Expedited timelines are available when your raise is on a clock.
Free deck audit

Raising your Seed round? Get the deck right first.

Drop your details and we'll send a free deck audit — then jump on a 15-minute intro call to walk through exactly what to fix before you pitch.

  • We reply within 24 hours
  • Complete founder confidentiality
Prefer to talk first? Book a 1:1 intro call
Get your free deck audit